NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) has been assigned an average rating of “Buy” from the six analysts that are presently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $43.33.
A number of equities analysts have recently issued reports on the stock. Scotiabank increased their price objective on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Thursday, February 27th. Needham & Company LLC dropped their price objective on shares of NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating for the company in a research note on Thursday, February 27th. UBS Group set a $41.00 price objective on shares of NewAmsterdam Pharma in a research note on Monday, March 3rd. HC Wainwright reiterated a “buy” rating and set a $48.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $40.00 target price on shares of NewAmsterdam Pharma in a research report on Friday, January 24th.
View Our Latest Stock Analysis on NAMS
Insider Buying and Selling
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of the business. Frazier Life Sciences Management L.P. boosted its stake in shares of NewAmsterdam Pharma by 23.8% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 15,916,418 shares of the company’s stock valued at $409,052,000 after purchasing an additional 3,061,224 shares during the last quarter. Bain Capital Life Sciences Investors LLC boosted its stake in shares of NewAmsterdam Pharma by 2.3% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 10,719,110 shares of the company’s stock valued at $275,481,000 after purchasing an additional 245,197 shares during the last quarter. RA Capital Management L.P. boosted its stake in shares of NewAmsterdam Pharma by 9.7% in the 4th quarter. RA Capital Management L.P. now owns 8,845,000 shares of the company’s stock valued at $227,316,000 after purchasing an additional 781,000 shares during the last quarter. Deerfield Management Company L.P. Series C boosted its stake in shares of NewAmsterdam Pharma by 378.4% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 4,314,340 shares of the company’s stock valued at $110,879,000 after purchasing an additional 3,412,590 shares during the last quarter. Finally, Jennison Associates LLC boosted its stake in shares of NewAmsterdam Pharma by 291.9% in the 4th quarter. Jennison Associates LLC now owns 3,998,541 shares of the company’s stock valued at $102,763,000 after purchasing an additional 2,978,263 shares during the last quarter. Institutional investors own 89.89% of the company’s stock.
NewAmsterdam Pharma Trading Down 0.9 %
NASDAQ NAMS opened at $23.37 on Tuesday. The company has a fifty day simple moving average of $21.95 and a 200 day simple moving average of $20.75. The company has a market cap of $2.57 billion, a P/E ratio of -8.99 and a beta of -0.04. NewAmsterdam Pharma has a 1 year low of $15.19 and a 1 year high of $27.29.
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.47). The business had revenue of $12.77 million for the quarter, compared to analysts’ expectations of $3.30 million. Equities research analysts forecast that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.
About NewAmsterdam Pharma
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Recommended Stories
- Five stocks we like better than NewAmsterdam Pharma
- Using the MarketBeat Dividend Tax Calculator
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- The How And Why of Investing in Oil Stocks
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Ride Out The Recession With These Dividend Kings
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.